A developmental delay genetic test looks for DNA changes that may explain why a child is learning, moving, speaking, or developing daily-living skills later than expected. There is no single test named “the developmental delay test.” The evaluation may include chromosomal microarray, Fragile X testing, exome sequencing, genome sequencing, or a focused test chosen from the child’s features. A positive result can identify a specific syndrome, clarify health risks, guide surveillance or treatment, and provide recurrence information for the family. A negative result does not rule out a genetic cause because current methods cannot detect or interpret every type of variant. Results also need clinical context: developmental delay describes a pattern, not one disease, and non-genetic factors such as prematurity, infection, toxic exposure, hearing loss, or brain injury may contribute. Testing is most informative when paired with a detailed history, physical and neurologic examination, developmental assessment, and genetic counseling.
- Genetic testing may find a diagnosis even when a child has no recognizable syndrome or family history.
- Exome or genome sequencing is now commonly considered early in unexplained global developmental delay or intellectual disability.
- Chromosomal microarray detects missing or extra DNA segments, while sequencing detects many smaller variants in individual genes.
- A variant of uncertain significance is not a confirmed diagnosis and should not direct irreversible treatment by itself.
- Negative results may become informative later through reanalysis as gene–disease knowledge and laboratory methods improve.
Table of Contents
- Developmental Delay and Genetic Causes
- Tests Used in the Genetic Evaluation
- Choosing the Right Testing Path
- How to Read Positive, Negative, and Uncertain Results
- What a Diagnosis Can Change
- Inheritance and Family Testing
- Limitations, Missed Variants, and Reanalysis
- Preparing for Testing and Follow-Up
Developmental Delay and Genetic Causes
Developmental delay means that a young child has not reached expected milestones in one or more areas. These areas include gross motor skills, fine motor skills, language, thinking and problem-solving, social interaction, and everyday adaptive skills. Global developmental delay generally refers to significant delay in at least two developmental domains in a child younger than about 5 years. Intellectual disability is diagnosed later when limitations in intellectual and adaptive functioning can be assessed reliably.
Genetic causes include changes in chromosome number, deletions or duplications of chromosome segments, single-gene variants, repeat expansions, imprinting abnormalities, mitochondrial DNA variants, and more complex genomic changes. Some occur for the first time in the child, called de novo variants. Others are inherited from a parent who may be affected, mildly affected, or clinically unaffected because the condition has reduced penetrance or variable expression.
A child does not need distinctive facial features or a positive family history to have a genetic condition. Many disease-causing variants arise de novo, and some syndromes have subtle physical signs. Conversely, a family history can appear negative because relatives were never diagnosed, symptoms were mild, family size is small, or a recessive or X-linked condition was passed silently through carriers.
Genetic testing is only one part of the evaluation. Hearing and vision testing, review of newborn screening, pregnancy and birth history, growth measurements, neurologic examination, and assessment for autism, cerebral palsy, or attention problems may all be important. Depending on the presentation, clinicians may order brain imaging, electroencephalography, thyroid studies, lead testing, creatine kinase, metabolic tests, or other targeted investigations. Early intervention should proceed while the cause is being investigated; therapy does not need to wait for a molecular diagnosis.
Certain findings increase the likelihood of a genetic diagnosis, including congenital anomalies, seizures, abnormal head size, unusual growth, low muscle tone, movement disorder, differences in facial or body structure, vision or hearing loss, and a similarly affected relative. However, genomic testing can still identify a cause in children whose only apparent feature is unexplained developmental delay.
Tests Used in the Genetic Evaluation
Different technologies detect different kinds of DNA change. A normal result from one test does not mean another method will also be normal.
Chromosomal microarray
Chromosomal microarray, often abbreviated CMA, looks for copy-number variants: sections of DNA that are missing or duplicated. These changes can involve one gene or many genes. Microarray can detect much smaller imbalances than a traditional chromosome analysis, but it usually does not identify balanced rearrangements in which no DNA is gained or lost. It also does not reliably detect most single-letter DNA variants, repeat expansions, or all forms of mosaicism.
Some microarrays include single-nucleotide polymorphism probes that can reveal long regions of homozygosity. Such regions may suggest parental relatedness, uniparental disomy, or a recessive condition, but they do not by themselves provide a diagnosis. The laboratory may need additional testing to determine the significance.
Exome sequencing
Exome sequencing analyzes most protein-coding portions of genes, which make up roughly 1%–2% of the genome but contain a large proportion of known disease-causing variants. It can detect many single-nucleotide variants and small insertions or deletions across thousands of genes at once. Some laboratories also analyze copy-number changes from exome data, although sensitivity varies.
Exome sequencing is often performed as a trio using samples from the child and both biological parents. Trio analysis helps identify de novo variants, determine whether two variants are on different copies of a recessive gene, and filter inherited changes that are less likely to explain the child’s features. Testing only the child can still be useful but may produce more uncertain results and require later parental studies.
Genome sequencing
Genome sequencing examines coding and noncoding DNA and can detect a broader range of variants in one test. Depending on the laboratory and platform, it may identify single-nucleotide variants, small insertions and deletions, copy-number changes, structural variants, some repeat expansions, and mitochondrial variants. Genome sequencing does not detect every possible abnormality, and laboratories differ in what they validate and report.
Genome sequencing may be especially helpful after nondiagnostic microarray and exome testing, when structural variation is suspected, or when a program uses genome sequencing as an early comprehensive test. Rapid or ultrarapid genome sequencing can be used for critically ill infants and children when a fast diagnosis could immediately alter intensive care.
Fragile X and repeat-expansion testing
Fragile X syndrome is caused by a CGG repeat expansion in FMR1. Standard exome sequencing often does not detect this expansion reliably, so a separate repeat-size and methylation test may be needed. Fragile X testing is especially relevant in boys with unexplained developmental delay or intellectual disability, but females can also be affected.
Other repeat-expansion disorders are less common in early developmental delay but may be considered when the phenotype suggests them. The test must be designed for the specific repeat because routine sequencing may miss the expansion.
Targeted gene, panel, methylation, and mitochondrial tests
A focused test may be faster or more complete when a particular condition is strongly suspected. Examples include MECP2 analysis for classic Rett syndrome features, UBE3A-region methylation studies for Angelman or Prader-Willi syndrome, DMD testing for marked creatine kinase elevation and muscle weakness, or an epilepsy panel for a child with a defined seizure syndrome.
Mitochondrial testing may include mitochondrial DNA sequencing and deletion analysis, sometimes alongside nuclear genes. Tissue choice matters for selected mitochondrial variants because blood may not contain a detectable level later in life. Biochemical findings and the child’s organ involvement guide this evaluation.
| Test | Best at detecting | Common gaps |
|---|---|---|
| Chromosomal microarray | Deletions and duplications across the genome | Most single-gene variants, balanced rearrangements, many repeat expansions |
| Exome sequencing | Small variants in protein-coding genes | Many noncoding variants, some structural variants, repeat expansions, methylation changes |
| Genome sequencing | Broad range of small and structural variants | Some repeats, methylation disorders, low-level mosaicism, difficult genomic regions |
| Fragile X testing | FMR1 CGG repeat size and methylation | Other genes and chromosome-wide changes |
| Targeted testing | A suspected gene, repeat, imprinting region, or variant type | Causes outside the selected target |
Choosing the Right Testing Path
Current professional guidance increasingly supports exome or genome sequencing as a first- or second-tier test for children with unexplained developmental delay, intellectual disability, or congenital anomalies. Earlier use can avoid years of sequential single-gene tests and may be more efficient than a long diagnostic odyssey. Chromosomal microarray and Fragile X testing remain important in many pathways, and local practice, insurance coverage, phenotype, and laboratory capabilities influence order.
There is no universal sequence that fits every child. A clinician may begin with genome sequencing if it includes validated copy-number analysis and the health system supports it. Another may order microarray and Fragile X testing while arranging trio exome sequencing. If a recognizable syndrome is suspected, a targeted methylation, repeat-expansion, or single-gene test may provide the fastest and most reliable answer.
The phenotype should guide test design without making the evaluation too narrow. A detailed description of the child’s features, called phenotyping, helps the laboratory rank variants. Terms such as “developmental delay” alone are less useful than specific observations: walked at 30 months, no spoken words at age 3, episodic ataxia, acquired microcephaly, absent speech with a happy demeanor, or seizures triggered by fever.
Trio testing is often preferable when available. Parental samples can show whether a variant is de novo or inherited, clarify phase for recessive conditions, and reduce the number of uncertain findings. A biological parent’s sample may also reveal mosaicism or an unexpectedly mild presentation. When one or both parents are unavailable, other relatives or alternative analysis strategies can still be used.
Rapid testing is considered when a child is critically ill and a diagnosis could alter urgent management. A newborn with severe hypotonia, seizures, metabolic instability, cardiac disease, or multiple congenital anomalies may benefit from results in days rather than months. The laboratory and clinical team should define how quickly variants will be analyzed, confirmed, and communicated.
The consent discussion should cover more than sample collection. Families need to know what kinds of results can be returned, whether secondary findings are offered, whether parental relationships can be revealed, how data may be stored, and whether the laboratory will reanalyze the data. Secondary findings are medically actionable variants unrelated to the reason for testing, such as a hereditary cancer or cardiac-risk variant. Policies vary, and parents may have choices about receiving them.
How to Read Positive, Negative, and Uncertain Results
A laboratory classifies variants using evidence about population frequency, predicted effect, laboratory studies, inheritance, reported patients, and fit with the child’s features. The classification can change as evidence grows.
Pathogenic or likely pathogenic result
A pathogenic or likely pathogenic variant may establish a molecular diagnosis when it matches the condition’s inheritance and the child’s phenotype. For a dominant disorder, one disease-causing variant may be sufficient. For a recessive disorder, two pathogenic variants usually must affect the two copies of the same gene. An X-linked result is interpreted according to the child’s sex chromosomes, gene, and condition.
“Likely pathogenic” is not a weak or preliminary label; it means the laboratory has strong evidence that the variant causes disease, although not enough for the highest classification. The clinician still must decide whether it explains all, some, or none of the child’s findings. A child can have more than one diagnosis.
Variant of uncertain significance
A variant of uncertain significance, or VUS, has insufficient or conflicting evidence. It should not be treated as a confirmed cause. Parental testing may help: a de novo variant in a gene that closely matches the phenotype can add evidence, while inheritance from a healthy parent may reduce concern for some dominant disorders. Neither observation is automatically decisive because penetrance and expression vary.
Families should avoid screening healthy relatives or changing major medical care solely because of a VUS unless a specialist has a separate clinical reason. The variant may later be reclassified as benign or pathogenic. The ordering clinic or laboratory should explain how reclassification updates are handled.
Negative or nondiagnostic result
A negative result means the test did not find a reportable variant that explains the presentation. It does not prove the cause is non-genetic. The causal change may lie in a region the test did not cover well, involve a variant type the method cannot detect, occur at a low mosaic level, affect a gene not yet linked to disease, or be present but not recognized as significant.
A nondiagnostic exome may lead to genome sequencing, repeat-expansion testing, methylation studies, mitochondrial evaluation, RNA analysis, or reanalysis. The choice should follow the child’s evolving phenotype rather than automatically ordering every available test.
Incidental, secondary, and carrier findings
Sequencing may reveal information unrelated to developmental delay. A secondary finding may identify a medically actionable risk in the child and sometimes a parent. Carrier findings indicate one variant for a recessive condition and usually do not explain the child’s delay, although exceptions exist. Laboratories differ in whether they report carrier status, pharmacogenetic variants, adult-onset conditions, or low-penetrance risk alleles.
What a Diagnosis Can Change
A genetic diagnosis can replace a descriptive label with a specific condition. This may end repeated testing, connect the family with specialists and support groups, and provide a more accurate explanation than assumptions about pregnancy, parenting, or an isolated developmental event.
Management changes vary. Some diagnoses point to a specific treatment, dietary intervention, vitamin or cofactor, enzyme replacement, antiseizure medication choice, or avoidance of a drug that can worsen symptoms. More often, the result guides surveillance: periodic heart tests, kidney imaging, hearing checks, eye examinations, endocrine screening, tumor surveillance, or monitoring for scoliosis and feeding problems.
Prognosis remains individual. Published descriptions often include people who were diagnosed because they had more severe features, and newer testing identifies milder presentations. A gene name does not determine exactly when a child will walk, speak, develop seizures, or live independently. The child’s observed development and health remain more informative than the broadest syndrome description.
A result can change care for relatives as well. A parent with the same variant may need medical evaluation. Siblings may qualify for targeted testing. Future pregnancies can be assessed through prenatal diagnosis or preimplantation genetic testing when the familial variant is known. These options require counseling and are personal choices, not obligations.
Inheritance and Family Testing
A de novo result means the variant was not detected in the tested blood samples of either parent. Recurrence risk is often low but not zero because a parent can have germline mosaicism—an affected egg or sperm cell line that is absent or too low to detect in blood. The exact estimate depends on the gene and condition.
In autosomal dominant inheritance, one altered gene copy can cause the condition. An affected person may have a 50% chance of passing the variant in each pregnancy, but severity can differ between relatives. Reduced penetrance means some carriers do not show clear symptoms.
Autosomal recessive conditions usually require a disease-causing variant in both gene copies. Parents are often healthy carriers. When both parents carry variants in the same gene, each pregnancy generally has a 25% chance of an affected child, a 50% chance of a carrier child, and a 25% chance of a child who inherited neither familial variant.
X-linked inheritance depends on the gene, the variant, and the child’s sex chromosomes. Females can be mildly or severely affected in many X-linked disorders because X-chromosome inactivation is variable. Describing women as “only carriers” can be inaccurate for conditions in which symptoms are possible.
Mitochondrial DNA variants are usually inherited through the egg, so maternal relatives may be relevant. The amount of altered mitochondrial DNA can vary among tissues and family members, making severity and recurrence more difficult to predict.
Copy-number variants and chromosome rearrangements may be de novo or inherited. If a child has a deletion or duplication, parental testing can determine whether a parent carries the same imbalance or a balanced rearrangement. This distinction can substantially change recurrence counseling.
Limitations, Missed Variants, and Reanalysis
Every report should be read with its technical limitations. Exome coverage is uneven; some exons and genes are difficult to sequence because of high GC content, pseudogenes, repetitive DNA, or homology. A “negative exome” may include poorly covered regions. Genome sequencing improves breadth but still has blind spots.
Mosaic variants may be missed when present in only a small fraction of blood cells or confined to another tissue. Skin fibroblasts, muscle, buccal cells, or affected tissue may be more informative in selected disorders. The decision to test another tissue should be made with a genetics specialist because collection can be invasive and laboratory validation differs.
Repeat expansions, methylation abnormalities, balanced translocations, mitochondrial heteroplasmy, and complex structural variants require specific attention. A broad test’s marketing name does not guarantee validated detection of each category. The report’s methods section should state what was actually analyzed.
Reanalysis is valuable because new gene–disease relationships are discovered and variant databases expand. A laboratory can revisit existing exome or genome data without recollecting the sample, although additional consent, fees, or a new order may be required. Reanalysis is often considered after about 1–3 years, sooner if the child develops important new features or a new syndrome is suspected.
A truly new analysis may be more useful than simple reissuance of the same report. Updated phenotype information should be sent to the laboratory. New seizures, regression, movement abnormalities, changes in head growth, organ involvement, or a newly diagnosed relative can move a previously overlooked variant to the top of the list.
Preparing for Testing and Follow-Up
Before the appointment, gather pregnancy and birth records, newborn screening results, developmental evaluations, imaging reports, laboratory results, and prior genetic tests. Write down milestone ages, any lost skills, seizure descriptions, growth concerns, feeding problems, sleep patterns, and therapies. A three-generation family history should include developmental differences, learning disability, autism, seizures, psychiatric illness, congenital anomalies, miscarriages, infant deaths, early-onset neurologic disease, and known genetic diagnoses. Record the family’s ancestry and whether the parents are biologically related, because both can influence test interpretation without determining the diagnosis.
Ask what test is being ordered, what it can and cannot detect, whether parental samples are needed, whether secondary findings will be reported, and how long results typically take. Clarify insurance authorization, possible out-of-pocket cost, sample requirements, and whether the laboratory offers financial assistance.
At the results visit, request the exact diagnosis, gene or chromosome finding, inheritance pattern, and variant classification in writing. Ask which health evaluations are recommended now, which symptoms need urgent attention, whether relatives should be tested, and when reanalysis should occur. A genetics professional can provide a family letter that explains targeted testing for relatives without disclosing unnecessary medical details.
Continue developmental therapies and school supports based on the child’s needs, not only the genetic label. Speech-language therapy, occupational therapy, physical therapy, augmentative communication, behavioral support, and individualized education can remain beneficial whether the test is positive or negative.
Seek prompt evaluation for developmental regression, new seizures, persistent vomiting, unusual sleepiness, loss of coordination, sudden weakness, breathing difficulty, or an acute change in behavior or awareness. These symptoms can signal a treatable neurologic or metabolic problem and should not be deferred while waiting for genetic results.
References
- Genetic Evaluation of the Child With Intellectual Disability or Global Developmental Delay 2025 (Clinical Report).
- Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG) 2021 (Guideline).
- Genetic and metabolic investigations for neurodevelopmental disorders: position statement of the Canadian College of Medical Geneticists (CCMG) 2023 (Position Statement).
- Genetic Diagnosis in Children with Developmental Delay 2024 (Review).
- Combining chromosomal microarray and clinical exome sequencing for genetic diagnosis of intellectual disability 2023 (Cohort Study).
- Genome sequencing demonstrates high diagnostic yield in children with undiagnosed global developmental delay/intellectual disability: a prospective study 2022 (Prospective Study).
Disclaimer
This article provides general education and cannot determine which test or diagnosis applies to an individual child. Developmental regression, seizures, breathing difficulty, or an acute loss of function requires prompt medical assessment. Genetic results should be interpreted by qualified clinicians and genetics professionals using the child’s history, examination, family information, and laboratory methods.
